New stock news | Jiangxi Bioscience is sprinting towards the Hong Kong Stock Exchange. The company is the largest provider of human use TAT in China and globally.

According to the disclosure of the Hong Kong Stock Exchange on April 11, Jiangxi Biologic Products Research Institute Co., Ltd. (hereinafter referred to as: Jiangxi Biologic) submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CICC and CMSC International as its joint sponsors. According to the prospectus, Jiangxi Biologic is the largest provider and exporter of human tetanus antitoxin ("human TAT") in China, and also a comprehensive anti-serum platform company. With over 50 years of professional experience in the research, production, and sales of anti-serum products, the company has established a solid market position domestically and internationally. Antiserum refers to a type of biological product containing immunoglobulins (also known as antibodies) or immunoglobulin F(ab')2 fragments, prepared from immune plasma. It is used to provide immune protection and treatment against various key infectious diseases (including tetanus, snakebite poisoning, and rabies, which require immediate intervention to neutralize toxins and save lives). These diseases continue to pose significant public health challenges, especially in developing countries with limited medical resources. The human anti-serum market in China and globally is huge, with significant growth potential. According to Frost & Sullivan data, the global human anti-serum market increased from $321 million in 2019 to $409 million in 2024, with a compound annual growth rate of 4.9%. It is expected to continue to increase to $821 million by 2028 and reach $2.095 billion by 2033, with compound annual growth rates of 19.1% and 20.6% between 2024 and 2028, and 2028 and 2033, respectively. The Chinese human anti-serum market increased from $48 million in 2019 to $64 million in 2024, with a compound annual growth rate of 5.9%, and is expected to continue to increase to $132 million by 2028 and reach $291 million by 2033, with compound annual growth rates of 19.9% and 17.0% between 2024 and 2028, and 2028 and 2033, respectively. According to Frost & Sullivan data, Jiangxi Biologic is the largest provider of human TAT in China and globally, with market shares of 65.8% and 36.6% by 2024 sales volume. Tetanus antitoxin is an anti-serum that provides immediate protection and treatment by neutralizing the toxin produced by the tetanus bacillus (the bacteria that cause tetanus), preventing and treating tetanus infection. In 2024, our total sales volume of human TAT was 25.4 million doses, with 13.2 million doses sold in China and 12.2 million doses exported to overseas markets. According to the same data, Jiangxi Biologic has maintained a dominant position in the Chinese human TAT market for 18 consecutive years, with a market share of over 50%. During the previous reporting period, the company's human TAT was exported to over 30 countries and regions in Asia and Africa, accounting for nearly 100% of China's exports. According to Frost & Sullivan data, by 2024 sales volume, the company is the largest provider of human TAT in the Philippines and Egypt, with market shares of approximately 90%. In terms of finances, in the fiscal years 2022, 2023, and 2024, Jiangxi Biologic achieved revenues of approximately 140 million, 198 million, and 221 million RMB respectively, with net profits of approximately 26.468 million, 55.481 million, and 75.14 million RMB respectively.